Outer Bio’s Yuna platform keeps living human skin functioning for a month, a longer window for testing what actually slows visible aging.
Cut a piece of human skin out of the body, and the clock starts ticking. Within days, it stops behaving like skin at all. The cells that once fought inflammation, rebuilt collagen and healed wounds start to shut down. For the scientists trying to figure out which compounds actually slow skin aging, that short window has always been the problem. You can’t watch a process that takes weeks to unfold if your test tissue is dead before week one even ends.
A new company thinks it has cracked that particular puzzle. Outer Bio came out of stealth this week with a platform called Yuna, which keeps full-thickness human skin (epidermis, dermis, immune cells and all) alive and testable for a full four weeks [1]. That’s long enough, the company says, to watch the slow biological processes behind aging skin actually happen in real time, in real human tissue.
Why four weeks changes the math
Skincare is a more than $100 billion industry, and yet in three decades of research, only one topical ingredient (here’s looking at you, retinoids) has earned FDA recognition for visibly improving aging skin.
Outer Bio’s pitch is that this isn’t for lack of trying or lack of money. It’s a technical bottleneck. The biology that matters for aging skin – how collagen rebuilds itself, how chronic low-grade inflammation (“inflammaging,” as longevity researchers have taken to calling it) does its damage, how senescent cells pile up and stop functioning – takes weeks to play out. Standard lab skin can’t survive that long, so researchers have effectively been asked to judge a marathon by watching the first hundred yards.
Yuna is built to remove that constraint. The tissue comes from donors spanning different ages, sexes, and skin tones, and it’s tracked continuously for the full month. Cell activity, tissue structure and protein signals. Each compound tested generates more than 30,000 data points, and the company says it has already amassed over 10 terabytes of data from more than 300 donors and 10,000 individual treatments.
Built to teach itself
The living-tissue data is designed to feed a machine-learning system that gets smarter with every test. Models trained on Yuna’s results help prioritize which compounds to try next, and each new result sharpens the next prediction. Outer Bio says its virtual screening library already covers 5.9 million compounds, with plans to eventually work through libraries in the billions.
“Skincare has never lacked demand or ambition. It has lacked the ability to study compounds and mechanisms in living human skin over a biologically relevant timeframe,” said Michael Polansky, co-founder and CEO of Outer Bio. “Most experimental platforms rely on reconstructed skin or cell monolayers. Those models can tell you whether a compound is toxic; they can’t tell you whether it works, because they lack the complexity and architecture of the real organ. And they fail within days, before the biology that matters even begins. We built Yuna to close that gap.”
The company has backed up that claim with public data. A preprint posted to bioRxiv documents Yuna reproducing three known skin conditions across the full four-week window, sustained psoriasis-like inflammation that responded to a JAK inhibitor, senescence markers in aged donor tissue that dropped after a senolytic treatment and UV damage that a topical sunscreen measurably reduced. None of those outcomes, Outer Bio argues, would have shown up in a shorter-lived model.
A longevity tool wearing a skincare label
It’s easy to file this under beauty industry news and move on. However, the underlying idea (senescent cells accumulating, inflammation quietly compounding, tissue losing its ability to repair itself) is the same biology longevity researchers chase in every other organ in the body. Skin just happens to be the one organ scientists can study without surgery, which makes it a useful proving ground for aging science more broadly.
If a platform like Yuna can reliably show that a senolytic combination reverses senescence markers in living tissue, that’s a data point for aging research well beyond what shows up on a store shelf. Outer Bio is opening the platform to select biopharma and ingredient partners, meaning its four-week window may end up informing therapeutics as much as it does the next serum.
